Showing 5251-5260 of 7125 results for "".
- Incyte Receives Positive CHMP Opinion for Opzelura Cream for the Treatment of Non-Segmental Vitiligohttps://practicaldermatology.com/news/incyte-receives-positive-chmp-opinion-for-opzelura-cream-for-the-treatment-of-non-segmental-vitiligo/2461576/The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of ruxolitinib cream (Opzelura) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
- Biomarkers May Predict AD Developmenthttps://practicaldermatology.com/news/biomarkers-may-predict-ad-development/2461575/An immune and lipid profile on the surface of the skin of infants may predict the development of atopic dermatitis months before the onset of illness. “The holy grail to deal with atopic dermatitis is to prevent it,” says study author
- Cetaphil Launches Initiative to Raise Awareness of Connection Between Clothing and Sensitive Skinhttps://practicaldermatology.com/news/cetaphil-launches-initiative-to-raise-awareness-of-connection-between-clothing-and-sensitive-skin/2461567/Cetaphil announced it is launching a new initiative this month that aims to raise awareness of the connection between our clothes and skin. The initiative includes a partnership with Hillary Taymour, designer and founder of fashion house Collina Strada, and board-certified dermatologist
- ASA Renews Support of SPOTS Programhttps://practicaldermatology.com/news/asa-renews-support-of-spots-program/2461565/The American Skin Association (ASA) announced the renewal of its support for the SPOTS (Sun Protection Outreach Teaching by Students) program. SPOTS is a community outreach program designed to teach students from preschool through high school about the importance of early detectio
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu
- Eye on the AD Pipeline: Dermavant Completes Enrollment of Phase 3 Trials of VTAMA in Adults and Children with ADhttps://practicaldermatology.com/news/eye-on-the-ad-pipeline-dermavant-completes-enrollment-of-phase-3-trials-of-vtama-in-adults-and-children-with-ad/2461561/Dermavant Sciences has completed patient enrollment in its ADORING 1 and 2 Phase 3 clinical trials of VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children as young as 2 years old. VTAMA cream is a novel, aryl hydrocarbon receptor agonist
- Experts React to Approval of Pfizer’s CIBINQO for Teens With Refractory ADhttps://practicaldermatology.com/news/fda-oks-pfizers-cibinqo-for-teens-with-refractory-ad/2461560/The US FDA has approved a supplemental New Drug Application (sNDA) for CIBINQO (abrocitinib, Pfizer). This move expands the drug's indication to include adolescents (12 to < 18 years) with refractory, moderate to severe atopic dermatitis (AD) whose disease is not adequately contr
- Kintor Pharma’s GT20029 Performs Well in Phase 1 Trial of Acne and Androgenetic Alopeciahttps://practicaldermatology.com/news/kintor-pharmas-gt20029-performs-well-in-phase-i-trial-of-acne-and-androgenetic-alopecia/2461559/Kintor Pharmaceutical Limited’s GT20029 was safe and well tolerated and had good pharmacokinetic characteristics in healthy people and people with androgenetic alopecia (AGA) or acne, according to a phase 1 clinical trial. GT20029 is the first topical PROTAC compound in the world
- Takeda Completes Acquisition of Nimbus’ TYK2 Subsidiaryhttps://practicaldermatology.com/news/takeda-completes-acquisition-of-nimbus-tyk2-subsidiary/2461552/Takeda has expanded its psoriasis treatment portfolio after completing its acquisition of Nimbus Lakshmi from Nimbus Therapeutics in a deal worth up to $6 billion. Under the agreement, which was announced on December 13, 2022, Takeda will acquire TAK-279, formerly known at Nim
- NRS Announces 2023 Rosacea Awareness Month Theme: Give New Treatments Time to Workhttps://practicaldermatology.com/news/nrs-announces-2023-rosacea-awareness-month-theme-give-new-treatments-enough-time-to-work/2461547/This Rosacea Awareness Month, the National Rosacea Society (NRS) is highlighting the importance of consistency and patience when trying new therapies. “Rosacea has no cure, but the signs and symptoms can go into remission through a combination of medical therapy and life